0001213900-17-009039.txt : 20170822 0001213900-17-009039.hdr.sgml : 20170822 20170822115229 ACCESSION NUMBER: 0001213900-17-009039 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20170822 DATE AS OF CHANGE: 20170822 EFFECTIVENESS DATE: 20170822 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Elucida Oncology, Inc. CENTRAL INDEX KEY: 0001704594 IRS NUMBER: 471358366 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-293250 FILM NUMBER: 171044534 BUSINESS ADDRESS: STREET 1: 228 PARK AVENUE SOUTH CITY: NEW YORK STATE: NY ZIP: 10003 BUSINESS PHONE: 805-691-9355 MAIL ADDRESS: STREET 1: 228 PARK AVENUE SOUTH CITY: NEW YORK STATE: NY ZIP: 10003 D 1 primary_doc.xml X0708 D LIVE 0001704594 Elucida Oncology, Inc. 228 PARK AVENUE SOUTH NEW YORK NY NEW YORK 10003 646-701-5931 DELAWARE None None Corporation true 2014 Edward Rosen c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Executive Officer Director Chief Executive Officer Ulrich Wiesner c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Steven Larson c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Robert A. Ruffolo c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Tim Boris c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Michelle Bradbury c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Sigurdur Olafsson c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Isaac Blech c/o Elucida Oncology, Inc. 228 Park Avenue South New York NY NEW YORK 10003 Director Biotechnology Decline to Disclose 06b false 2017-08-15 false true true false 25000 Maxim Group LLC 12078 None None 405 LEXINGTON AVENUE NEW YORK NY NEW YORK 10174 All States false 30000000 10859249 19140751 false 94 1000000 true 0 400000 Upon a closing of $15 million in the aggregate, Mr. Edward Rosen is entitled to the receive up to $400,000 relating to various consulting fees and the reimbursement of company expenses pursuant to the terms of his employment agreement. false Elucida Oncology, Inc. /s/ Edward Rosen Edward Rosen Chief Executive Officer 2017-08-22